Trial Profile
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2026
Price :
$35
*
At a glance
- Drugs Alectinib (Primary) ; Atezolizumab (Primary) ; Brigatinib (Primary) ; Cobimetinib (Primary) ; Entrectinib (Primary) ; Erlotinib (Primary) ; Everolimus (Primary) ; Ipatasertib (Primary) ; Ipilimumab (Primary) ; Itacitinib (Primary) ; Lapatinib (Primary) ; Nivolumab (Primary) ; Palbociclib (Primary) ; Pemigatinib (Primary) ; Pertuzumab (Primary) ; Ponatinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Vemurafenib (Primary) ; Vismodegib (Primary)
- Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Glioblastoma; Male breast cancer; Non-small cell lung cancer; Solid tumours
- Focus Proof of concept; Therapeutic Use
- Acronyms ROME
Most Recent Events
- 25 Mar 2026 According to NetraMark media release, The collaboration is expected to generate long-term value by combining FMP's oncology datasets with NetraAI's advanced analytical capabilities to uncover clinically actionable insights for the ROME program.
- 25 Mar 2026 According to NetraMark media release, The collaboration will apply its proprietary NetraAI platform to analyze the ROME dataset and other oncology datasets made available by FMP, with the goal of uncovering clinically meaningful patient subpopulations and biomarker-anchored treatment patterns. and The initial phase of the collaboration will focus on discovering and validating high-signal patient subgroups within the ROME dataset.
- 25 Mar 2026 According to NetraMark media release, The ROME trial, reported in Nature Medicine, is a multicentre, randomized, open-label phase 2 study comparing tailored treatment to standard of care.